Goldman Sachs
AMLX icon

Goldman Sachs’s Amylyx Pharmaceuticals AMLX Stock Holding History

Goldman Sachs’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.5M Buy
2,625,991
+12,770
+0.5% +$180K ﹤0.01% 1838
2025
Q4 		$31.6M Buy
2,613,221
+602,588
+30% +$8.18M ﹤0.01% 1928
2025
Q3 		$27.3M Buy
2,010,633
+712,651
+55% +$6.71M ﹤0.01% 1953
2025
Q2 		$8.32M Sell
1,297,982
-704,979
-35% -$3.43M ﹤0.01% 2929
2025
Q1 		$7.09M Buy
2,002,961
+143,065
+8% +$509K ﹤0.01% 3017
2024
Q4 		$7.03M Buy
1,859,896
+246,033
+15% +$1.16M ﹤0.01% 3119
2024
Q3 		$5.23M Sell
1,613,863
-996,557
-38% -$2.24M ﹤0.01% 3310
2024
Q2 		$4.96M Sell
2,610,420
-332,766
-11% -$645K ﹤0.01% 3161
2024
Q1 		$8.36M Buy
2,943,186
+1,686,325
+134% +$22.1M ﹤0.01% 2640
2023
Q4 		$18.5M Buy
1,256,861
+69,733
+6% +$1.07M ﹤0.01% 1977
2023
Q3 		$21.7M Sell
1,187,128
-163,350
-12% -$3.45M ﹤0.01% 1730
2023
Q2 		$29.1M Sell
1,350,478
-15,694
-1% -$424K 0.01% 1533
2023
Q1 		$40.1M Buy
1,366,172
+329,902
+32% +$11.5M 0.01% 1227
2022
Q4 		$38.3M Buy
1,036,270
+656,871
+173% +$23.3M 0.01% 1389
2022
Q3 		$10.7M Buy
+379,399
New +$9.47M ﹤0.01% 2445

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Goldman Sachs's AMLX Position: Q1 2026 in Review

Goldman Sachs increased its Amylyx Pharmaceuticals (AMLX) stake by 0.49% in Q1 2026, buying an estimated $180K and bringing the position to 2,625,991 shares worth $36.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1838.

Goldman Sachs first reported a position in AMLX in Q3 2022 and has held it in 15 quarters since. The position peaked at $40.1M in Q1 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Goldman Sachs held 2,625,991 shares of Amylyx Pharmaceuticals worth $36.5M as of Q1 2026.
  • Goldman Sachs bought 12,770 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $180K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1838 holding.
  • Goldman Sachs first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Goldman Sachs's Amylyx Pharmaceuticals position peaked at $40.1M in Q1 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.